Objectives: Previous retrospective studies demonstrated that circulating tumor cells (CTCs)
subtypes correlate with overall survival in patients with pancreatic ductal adenocarcinoma …

Objective: We assessed circulating tumor cells (CTCs) with epithelial and mesenchymal
phenotypes as a potential prognostic biomarker for patients with pancreatic …

Background: Current diagnosis and staging of pancreatic ductal adenocarcinoma (PDAC)
has important limitations and better biomarkers are needed to guide initial therapy. We …

Background Occult metastatic tumors, below imaging thresholds, are a limitation of staging
systems that rely on cross-sectional imaging alone and are a cause of the routine …

Purpose: Pancreatic cancer is one of the most devastating diseases with a 5-year survival
rate of 3% to 5%. Here, we investigated whether circulating tumor cells (CTC) may predict …

Background Pancreatic carcinoma is one of the leading causes of cancer-related mortality.
At the time of diagnosis, 30% of patients present with a locally advanced pancreatic …

Abstract Purpose: Circulating tumor cells (CTCs) have been identified in the blood of
patients with pancreatic adenocarcinoma (PDAC), but little is known about the exact …

Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and
Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a …

The poor prognosis of pancreatic cancer patients is associated with the frequent and early
dissemination of the disease, as well as late detection due to unspecific and late symptoms …

Background It has been shown that circulating tumor cells in peripheral blood can be used
to predict survival in patients with breast, prostate and other epithelial tumors. In the present …